Foreign Firms Among Casualties As China FDA Clears Clinical Data Smog
This article was originally published in PharmAsia News
Executive Summary
Although products from foreign pharma companies in general are considered to be of high quality in China, a number of such firms, including India’s Sun Pharma, have retracted product registration applications as regulatory authorities widen a crackdown on the quality of the clinical data included in such filings.